Dipyridamole Tablets

Manufacturer
Rising Pharmaceuticals, Inc. | Murty Pharmaceuticals, Inc.
Effective date
2022-12-28
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
10
Source
legacy-cache
Hydrated at
2026-08-01 21:42:31

Label at a glance#

ProductDIPYRIDAMOLE
Active ingredientDIPYRIDAMOLE
Label structure16 sections

Indications and uses

Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.

Dosage and administration

Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75 mg to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Dipyridamole Tablets, USP

25 mg, 50 mg, and 75 mg tablets

Rx only

Prescribing Information

DESCRIPTION

DESCRIPTION SECTION

Dipyridamole USP is a platelet inhibitor chemically described as 2,2',2",2"'-[(4,8- Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:

structural formulastructural formula

Dipyridamole is an odorless yellow crystalline powder, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and practically insoluble in water.

Dipyridamole Tablets, USP for oral administration contain:

Active Ingredient TABLETS 25 mg, 50 mg, and 75 mg: dipyridamole USP 25 mg, 50 mg and 75 mg, respectively.

Inactive Ingredients TABLETS 25 mg, 50 mg, and 75 mg: corn starch, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

It is believed that platelet reactivity and interaction with prosthetic cardiac valve surfaces, resulting in abnormally shortened platelet survival time, is a significant factor in thromboembolic complications occurring in connection with prosthetic heart valve replacement.

Dipyridamole tablets have been found to lengthen abnormally shortened platelet survival time in a dose-dependent manner.

In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, dipyridamole tablets, in combination with warfarin, decreased the incidence of postoperative thromboembolic events by 62 to 91 % compared to warfarin treatment alone. The incidence of thromboembolic events in patients receiving the combination of dipyridamole tablets and warfarin ranged from 1.2 to 1.8%. In three additional studies involving 392 patients taking dipyridamole tablets and coumarin-like anticoagulants, the incidence of thromboembolic events ranged from 2.3 to 6.9%.

In these trials, the coumarin anticoagulant was begun between 24 hours and 4 days postoperatively, and the dipyridamole tablets were begun between 24 hours and 10 days postoperatively. The length of follow-up in these trials varied from 1 to 2 years.

Dipyridamole tablets do not influence prothrombin time or activity measurements when administered with warfarin.

Mechanism of Action

MECHANISM OF ACTION SECTION

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5-1.9 μg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A 2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'- adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).

Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP- PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).

Hemodynamics

SPL UNCLASSIFIED SECTION

In dogs intraduodenal doses of dipyridamole of 0.5 to 4.0 mg/kg produced dose-related decreases in systemic and coronary vascular resistance leading to decreases in systemic blood pressure and increases in coronary blood flow. Onset of action was in about 24 minutes and effects persisted for about 3 hours.

Similar effects were observed following intravenous dipyridamole in doses ranging from 0.025 to 2.0 mg/kg.

In man the same qualitative hemodynamic effects have been observed. However, acute intravenous administration of dipyridamole may worsen regional myocardial perfusion distal to partial occlusion of coronary arteries.

Pharmacokinetics and Metabolism

SPL UNCLASSIFIED SECTION

Following an oral dose of dipyridamole tablets, the average time to peak concentration is about 75 minutes. The decline in plasma concentration following a dose of dipyridamole tablets fits a two-compartment model. The alpha half-life (the initial decline following peak concentration) is approximately 40 minutes. The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours. Dipyridamole is highly bound to plasma proteins. It is metabolized in the liver where it is conjugated as a glucuronide and excreted with the bile.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hypersensitivity to dipyridamole and any of the other components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Coronary Artery Disease: Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g., unstable angina or recently sustained myocardial infarction). Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.

Hepatic Insufficiency: Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration.

Hypotension: Dipyridamole should be used with caution in patients with hypotension since it can produce peripheral vasodilation.

Stress Testing with Intravenous Dipyridamole and Other Adenosinergic Agents: Clinical experience suggests that patients being treated with dipyridamole tablets who also require pharmacological stress testing with intravenous dipyridamole or other adenosinergic agents (e.g. adenosine, regadenoson) should interrupt dipyridamole tablets for 48 hours prior to stress testing.

Intake of dipyridamole tablets within 48 hours prior to stress testing with intravenous dipyridamole or other adenosinergic agents may increase the risk for cardiovascular side effects of these agents and may impair the sensitivity of the test.

Laboratory Tests

LABORATORY TESTS SECTION

Dipyridamole has been associated with elevated hepatic enzymes.

Drug Interactions

DRUG INTERACTIONS SECTION

No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets. The following information was obtained from the literature.

Adenosinergic agents (e.g., adenosine, regadenoson): Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A-receptor agonist. The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing.

Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m 2 basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats. Mutagenicity tests of dipyridamole with bacterial and mammalian cell systems were negative. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m 2 basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m 2  basis).

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

Reproduction studies have been performed in mice, rabbits and rats at oral dipyridamole doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1 ½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m 2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, dipyridamole tablets should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

As dipyridamole is excreted in human milk, caution should be exercised when dipyridamole tablets are administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in the pediatric population below the age of 12 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of dipyridamole tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and  placebo:

Table 1 Adverse Reactions Reported in 2 Heart Valve Replacement Trials
Adverse
Reaction
Dipyridamole Tablets/
Warfarin
Placebo/
Warfarin
Number of patients 147 170
Dizziness 13.6% 8.2%
Abdominal distress 6.1% 3.5%
Headache 2.3% 0.0%
Rash 2.3% 1.1%

Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication.

When dipyridamole tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed.

In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis, hypotension, palpitation, and tachycardia.

OVERDOSAGE

OVERDOSAGE SECTION

In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential. Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.

Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole overdose. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75 mg to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.

HOW SUPPLIED

HOW SUPPLIED SECTION

Dipyridamole Tablets, USP are available as round, white, film-coated tablets of 25 mg, 50 mg, and 75 mg coded 81/SL, 82/SL, and 83/SL, respectively.

They are available in bottles of 100 tablets as indicated below:

25 mg Tablets (NDC 64980-133-01)

50 mg Tablets (NDC 64980-134-01)

75 mg Tablets (NDC 64980-135-01)

They are available in bottles of 1000 tablets as indicated below:

25 mg Tablets (NDC 64980-133-10)

50 mg Tablets (NDC 64980-134-10)

75 mg Tablets (NDC 64980-135-10)

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.

For medical inquiries, please visit the website www.risingpharma.com or call 1-866-562-4597.

Distributed by:
Rising Pharmaceuticals, Inc.,  
Saddle Brook, NJ 07663 USA

Manufactured by:
Murty Pharmaceuticals, Inc., 
Lexington, KY 40509 USA

Revised: December 2019 

P112-03

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container 25 mg

Rising            NDC 64980-133-01

Dipyridamole
Tablets, USP

25 mg

100 Tablets

Rx only

PRINCIPAL DISPLAY PANEL Container 25 mg Rising NDC 64980-133-01 Dipyridamole Tablets, USP 25 mg 100 Tablets Rx onlyPRINCIPAL DISPLAY PANEL Container 25 mg Rising NDC 64980-133-01 Dipyridamole Tablets, USP 25 mg 100 Tablets Rx only

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container 25 mg

Rising            NDC 64980-133-10

Dipyridamole
Tablets, USP

25 mg

1000 Tablets

Rx only

PRINCIPAL DISPLAY PANEL Container 25 mg Rising NDC 64980-133-10 Dipyridamole Tablets, USP 25 mg 1000 Tablets Rx onlyPRINCIPAL DISPLAY PANEL Container 25 mg Rising NDC 64980-133-10 Dipyridamole Tablets, USP 25 mg 1000 Tablets Rx only

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container 50 mg

Rising            NDC 64980-134-01

Dipyridamole
Tablets, USP

50 mg

100 Tablets

Rx only

PRINCIPAL DISPLAY PANEL Container 50 mg Rising NDC 64980-134-01 Dipyridamole Tablets, USP 50 mg 100 Tablets Rx onlyPRINCIPAL DISPLAY PANEL Container 50 mg Rising NDC 64980-134-01 Dipyridamole Tablets, USP 50 mg 100 Tablets Rx only

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container 50 mg

Rising            NDC 64980-134-10

Dipyridamole
Tablets, USP

50 mg

1000 Tablets

Rx only

PRINCIPAL DISPLAY PANEL Container 50 mg Rising NDC 64980-134-10 Dipyridamole Tablets, USP 50 mg 1000 Tablets Rx onlyPRINCIPAL DISPLAY PANEL Container 50 mg Rising NDC 64980-134-10 Dipyridamole Tablets, USP 50 mg 1000 Tablets Rx only

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container 75 mg

Rising            NDC 64980-135-01

Dipyridamole
Tablets, USP

75 mg

100 Tablets

Rx only

PRINCIPAL DISPLAY PANEL Container 75 mg Rising NDC 64980-135-01 Dipyridamole Tablets, USP 75 mg 100 Tablets Rx onlyPRINCIPAL DISPLAY PANEL Container 75 mg Rising NDC 64980-135-01 Dipyridamole Tablets, USP 75 mg 100 Tablets Rx only

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container 75 mg

Rising            NDC 64980-135-10

Dipyridamole
Tablets, USP

75 mg

1000 Tablets

Rx only

PRINCIPAL DISPLAY PANEL Container 75 mg Rising NDC 64980-135-10 Dipyridamole Tablets, USP 75 mg 1000 Tablets Rx onlyPRINCIPAL DISPLAY PANEL Container 75 mg Rising NDC 64980-135-10 Dipyridamole Tablets, USP 75 mg 1000 Tablets Rx only

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
64980-133DIPYRIDAMOLE TABLET, FILM COATED [RISING PHARMACEUTICALS, INC.]10Legacy NDC20221229_0146650f-d6e6-4a9c-8925-415b3c92b0e7.zip
64980-134DIPYRIDAMOLE TABLET, FILM COATED [RISING PHARMACEUTICALS, INC.]10Legacy NDC20221229_0146650f-d6e6-4a9c-8925-415b3c92b0e7.zip
64980-135DIPYRIDAMOLE TABLET, FILM COATED [RISING PHARMACEUTICALS, INC.]10Legacy NDC20221229_0146650f-d6e6-4a9c-8925-415b3c92b0e7.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
64980-133-01EA - Each64980-133bba46e79-4ac1-4998-be52-cef090692e5412013-02-13
64980-133-10EA - Each64980-133d6cfb847-c425-439f-a10c-fa72d8ffe97212013-02-13
64980-134-01EA - Each64980-1349bb0d0b3-0b33-479c-a700-fdf084f79eb812013-02-13
64980-134-10EA - Each64980-13443857bed-0ade-48bf-afea-138d08624ea712013-02-13
64980-135-01EA - Each64980-1357d9ec7e9-d594-492c-80e2-3773716bbe4112013-02-13
64980-135-10EA - Each64980-1357c0c383b-1d3c-4cf6-bdfc-28e99cabcf2112013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
DIPYRIDAMOLEACTIVE INGREDIENT64ALC7F90C3
DIPYRIDAMOLEACTIVE MOIETY64ALC7F90C3
HYDROXYPROPYL CELLULOSEINACTIVE INGREDIENTRFW2ET671P3
LACTOSE MONOHYDRATEINACTIVE INGREDIENTEWQ57Q8I5X3
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I303
POLYETHYLENE GLYCOLSINACTIVE INGREDIENT3WJQ0SDW1A3
POVIDONEINACTIVE INGREDIENTFZ989GH94E3
STARCH, CORNINACTIVE INGREDIENTO8232NY3SJ3
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 24 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 196 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET / ORAL4384 mgExact identifier — unii candidate
38 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION / SUBCUTANEOUS98 mgExact identifier — unii candidate
38 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ECAPSULE, EXTENDED RELEASE / ORAL56 mgExact identifier — unii candidate
30 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PTABLET / SUBLINGUAL1 mgExact identifier — unii candidate
27 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XPOWDER / ORAL50 mgExact identifier — unii candidate
38 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, FILM COATED, EXTENDED RELEASE / ORAL11 mgExact identifier — unii candidate
40 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET / SUBLINGUAL6 mgExact identifier — unii candidate
30 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJTABLET, COATED / ORAL256 mgExact identifier — unii candidate
22 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94EINJECTION / INTRAMUSCULAR0.2 %w/vExact identifier — unii candidate
30 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPFILM, SOLUBLE / BUCCAL11 mgExact identifier — unii candidate
40 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii candidate
39 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR214 mgExact identifier — unii candidate
38 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, CHEWABLE / ORAL1412 mgExact identifier — unii candidate
38 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET / ORAL216 mgExact identifier — unii candidate
30 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCREAM / TOPICAL80 mgExact identifier — unii candidate
40 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPSYSTEM / TOPICAL420 mgExact identifier — unii candidate
40 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, EXTENDED RELEASE / ORAL117 mgExact identifier — unii candidate
39 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJDROPS / ORALNAExact identifier — unii candidate
22 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XGRANULE, FOR SUSPENSION / ORALNAExact identifier — unii candidate
38 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XCAPSULE, COATED PELLETS / ORAL265 mgExact identifier — unii candidate
38 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ESUSPENSION / ORAL20 mg/5mlExact identifier — unii candidate
30 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET, FILM COATED, EXTENDED RELEASE / ORAL17 mgExact identifier — unii candidate
30 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PTABLET, FILM COATED, EXTENDED RELEASE / ORAL187.6 mgExact identifier — unii candidate
27 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CREAM / TOPICALNAExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / SUBLINGUAL17.5 mgExact identifier — unii candidate
39 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPINSERT, EXTENDED RELEASE / OPHTHALMIC0.4 mgExact identifier — unii candidate
40 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XPOWDER, FOR SUSPENSION / ORALNAExact identifier — unii candidate
38 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
39 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPFILM, EXTENDED RELEASE / TRANSDERMALNAExact identifier — unii candidate
40 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE / ORAL629 mgExact identifier — unii candidate
39 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, FILM COATED, EXTENDED RELEASE / ORAL520 mgExact identifier — unii candidate
38 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, DELAYED RELEASE / ORAL2313 mgExact identifier — unii candidate
38 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30WAFER / ORAL66 mgExact identifier — unii candidate
39 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPOINTMENT / TOPICAL5 %w/wExact identifier — unii candidate
40 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE, FOR SUSPENSION / ORAL14 mgExact identifier — unii candidate
39 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PGEL / TOPICAL222 mgExact identifier — unii candidate
27 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER / RESPIRATORY (INHALATION)0.13 mgExact identifier — unii candidate
39 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ECAPSULE, COATED PELLETS / ORAL10.03 mgExact identifier — unii candidate
30 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ESUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
30 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PTABLET, ORALLY DISINTEGRATING / ORAL4 mgExact identifier — unii candidate
27 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PTABLET, CHEWABLE / ORAL10 mgExact identifier — unii candidate
27 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION / ORAL64 mgExact identifier — unii candidate
39 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XPOWDER / RESPIRATORY (INHALATION)50 mgExact identifier — unii candidate
38 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, CHEWABLE / ORAL127 mgExact identifier — unii candidate
39 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XINSERT / VAGINAL2282 mgExact identifier — unii candidate
38 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SYSTEM / INTRAVITREAL0.02 mgExact identifier — unii candidate
39 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PCAPSULE, DELAYED RELEASE / ORAL150 mgExact identifier — unii candidate
27 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION, EXTENDED RELEASE / ORAL71 mgExact identifier — unii candidate
39 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJTABLET / SUBLINGUAL409 mgExact identifier — unii candidate
22 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJTABLET / ORAL1116 mgExact identifier — unii candidate
22 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PLOZENGE / ORAL500 mgExact identifier — unii candidate
27 equally ranked IID candidates
HYDROXYPROPYL CELLULOSEHYDROXYPROPYL CELLULOSE (1600000 WAMW)RFW2ET671PSUSPENSION / ORAL100 mgExact identifier — unii candidate
27 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, FILM COATED / ORAL968 mgExact identifier — unii candidate
38 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPGUM, CHEWING / BUCCAL182 mgExact identifier — unii candidate
40 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL42 mgExact identifier — unii candidate
40 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJCAPSULE, COATED, EXTENDED RELEASE / ORAL19 mgExact identifier — unii candidate
22 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION / INTRAVENOUS900 mgExact identifier — unii candidate
38 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET, FOR SUSPENSION / ORAL2 mgExact identifier — unii candidate
30 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XCAPSULE, EXTENDED RELEASE / ORAL5364 mgExact identifier — unii candidate
38 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040733-001DIPYRIDAMOLEDIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13
A040733-002DIPYRIDAMOLEDIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13
A040733-003DIPYRIDAMOLEDIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A040733-001AB
A040733-002AB
A040733-003AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 135 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13d4dbc9d85df4…
2026-11-14 07:37:172026-10A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13d4dbc9d85df4…
2026-11-14 07:37:172026-10A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13d4dbc9d85df4…
2026-10-15 13:18:302026-09A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13c2088c7a36db…
2026-10-15 13:18:302026-09A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13c2088c7a36db…
2026-10-15 13:18:302026-09A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13c2088c7a36db…
2026-09-14 22:38:342026-08A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-1384e616aacf4f…
2026-09-14 22:38:342026-08A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-1384e616aacf4f…
2026-09-14 22:38:342026-08A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-1384e616aacf4f…
2026-08-18 06:07:402026-07A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13caaa826d4ba7…
2026-08-18 06:07:402026-07A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13caaa826d4ba7…
2026-08-18 06:07:402026-07A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13011fe1cb6892…
2026-02-19 14:30 UTC2026-02A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13011fe1cb6892…
2026-02-19 14:30 UTC2026-02A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-1331067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-1331067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-1331067a03dcf5…
2025-08-23 18:47 UTC2025-08A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-136a471c1ec25d…
2025-08-23 18:47 UTC2025-08A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-136a471c1ec25d…
2025-08-23 18:47 UTC2025-08A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-136a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-1303ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-1303ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-1303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-132680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-132680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-132680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-135bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-135bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-135bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040733-002DIPYRIDAMOLE50MGTABLET / ORALAB2007-02-13d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040733-003DIPYRIDAMOLE75MGTABLET / ORALAB2007-02-13d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040733-001DIPYRIDAMOLE25MGTABLET / ORALAB2007-02-13d06236e962d9…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 4 · 135 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A040733-001AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A040733-002AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A040733-003AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A040733-001AB1c2088c7a36db…
2026-10-15 13:18:302026-09A040733-002AB1c2088c7a36db…
2026-10-15 13:18:302026-09A040733-003AB1c2088c7a36db…
2026-09-14 22:38:342026-08A040733-001AB184e616aacf4f…
2026-09-14 22:38:342026-08A040733-002AB184e616aacf4f…
2026-09-14 22:38:342026-08A040733-003AB184e616aacf4f…
2026-08-18 06:07:402026-07A040733-001AB1caaa826d4ba7…
2026-08-18 06:07:402026-07A040733-002AB1caaa826d4ba7…
2026-08-18 06:07:402026-07A040733-003AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040733-001AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A040733-002AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A040733-003AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040733-001AB131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040733-002AB131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040733-003AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040733-001AB16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A040733-002AB16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A040733-003AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040733-001AB1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040733-002AB1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040733-003AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040733-001AB1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040733-002AB1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040733-003AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040733-001AB103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040733-002AB103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040733-003AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040733-001AB12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040733-002AB12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040733-003AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040733-001AB15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040733-002AB15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040733-003AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040733-001AB1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040733-002AB1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040733-003AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040733-001AB1d06236e962d9…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
9c81f7a2-3821-4fd1-847f-30eb4da0b0bc0146650f-d6e6-4a9c-8925-415b3c92b0e72025-08-05Adverse reactionsExact identifier
spl set id: 0146650f-d6e6-4a9c-8925-415b3c92b0e7

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.